Induction chemotherapy with albumin-bound paclitaxel plus lobaplatin followed by concurrent radiochemotherapy for locally advanced esophageal cancer

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 11

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Trials Study

World J Gastrointest Oncol. Nov 15, 2021; 13(11): 1781-1790
Published online Nov 15, 2021. doi: 10.4251/wjgo.v13.i11.1781

Table 3 Adverse events (n = 29)

	Grade 1 or 2 (%)	Grade 3 (%)
Hematologic toxicities
Anemia	3.85	0
Leukopenia	69.23	10.35
Neutropenia	61.54	6.9
Thrombocytopenia	15.4	0
Non-hematologic toxicities
Decreased appetite	13.79	0
Fatigue	13.79	0
Radiation-induced esophagitis	34.48	13.79
Decreased body weight	3.45	0
Abnormal liver function	3.45	0

Citation: Yan MH, Liu F, Qu BL, Cai BN, Yu W, Dai XK. Induction chemotherapy with albumin-bound paclitaxel plus lobaplatin followed by concurrent radiochemotherapy for locally advanced esophageal cancer. World J Gastrointest Oncol 2021; 13(11): 1781-1790
URL: https://www.wjgnet.com/1948-5204/full/v13/i11/1781.htm
DOI: https://dx.doi.org/10.4251/wjgo.v13.i11.1781

Yan MH, Liu F, Qu BL, Cai BN, Yu W, Dai XK. Induction chemotherapy with albumin-bound paclitaxel plus lobaplatin followed by concurrent radiochemotherapy for locally advanced esophageal cancer. World J Gastrointest Oncol 2021; 13(11): 1781-1790 [PMID: 34853650 DOI: 10.4251/wjgo.v13.i11.1781]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.